Nanobiotix S.A. Stock Price, News & Analysis

NBTXR3, developed by Nanobiotix, shows promising preclinical results presented at the 36th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC). The data indicate that radiotherapy-activated NBTXR3 enhances CD8+ T cell infiltration and modulates the T cell receptor repertoire, suggesting improved immune priming. Additionally, the combination of NBTXR3 with anti-PD-1, anti-LAG3, and anti-TIGIT substantially elevated anti-tumor immune response activities. These findings underscore potential advancements in combination therapies for solid tumors.

Nanobiotix announced its latest regulatory update as of October 31, 2021, reporting a total of 34,825,872 shares outstanding. The gross total number of voting rights is 36,003,389, while the net total is 35,983,625. This update is in compliance with the French Commercial Code and aims to ensure transparency in shareholder communications. Established in 2003, the company focuses on innovative therapeutic solutions in oncology, with its lead candidate NBTXR3 already authorized in Europe for treating soft tissue sarcoma.

Nanobiotix, a late-stage biotechnology company specializing in innovative cancer treatments, announced CEO Laurent Levy's participation in a fireside chat at the Jefferies London Healthcare Conference. Scheduled for November 16, 2021, at 3:40 PM GMT/10:40 AM EST, the event will be live-streamed on the company's website. Established in 2003, Nanobiotix focuses on physics-based therapies and holds over 30 patents. Its lead product, NBTXR3, is authorized in Europe for soft tissue sarcoma under the brand name Hensify®.

Nanobiotix has released first survival data from its NBTXR3 program at the ASTRO 2021 Annual Meeting. In a group of 41 elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC), the median overall survival (mOS) was 18.1 months and median progression-free survival (mPFS) was 10.6 months. The best objective response rate (ORR) was 85.4%, with a complete response rate (CRR) of 63.4%. These positive findings support future phase III trials aimed at this challenging patient group.

Nanobiotix (NASDAQ: NBTX) reported progress in its oncology clinical programs, highlighting published preclinical data in the Red Journal about NBTXR3 combined with radiotherapy and anti-PD-1. The company is set to present survival data from its head and neck cancer program at the ASTRO meeting from October 24-27, 2021. As of September 30, 2021, Nanobiotix had €89.8 million in cash. It is on track to activate clinical trial sites for its pivotal phase III study, NANORAY-312, in the coming weeks.

Nanobiotix announces its total number of shares and voting rights as of September 30, 2021. The company had 34,825,872 outstanding shares with 35,999,889 total voting rights gross and 35,986,273 total voting rights net. This report complies with the French Commercial Code and the General Regulations of the Autorité des Marchés Financiers. As a clinical biotechnology company, Nanobiotix focuses on innovative therapeutic approaches in oncology with its lead candidate NBTXR3 already authorized in Europe for treating soft tissue sarcoma under the brand name Hensify®.

NANOBIOTIX (NASDAQ: NBTX) announced five presentations at the ASTRO 2021 Annual Meeting, from October 24-27. Key highlights include:

• Poster presentation by Pr. Christophe Le Tourneau on phase I data for NBTXR3 in head and neck cancer.
• Oral presentation by Dr. Tanguy Y. Seiwert discussing NBTXR3's potential effects as a single agent and with anti-PD-1.
• Dr. Sylvie Bonvalot's follow-up on phase II/III STS study.

NBTXR3, a novel oncology product, is designed for use with radiotherapy, showing promise in treating solid tumors.

Nanobiotix (NASDAQ: NBTX) announced the publication of preclinical data in the International Journal of Radiation Oncology, showcasing the potential of NBTXR3 combined with radiotherapy and anti-PD-1 to enhance tumor treatment. The study reveals that NBTXR3 effectively controls tumor growth in both sensitive and resistant models, improves immune response, and reduces metastasis. This research supports NBTXR3's exploration as a novel treatment option for metastatic lung cancer, aiming to convert irradiated tumors into 'self-vaccines' for broader therapeutic use.

Nanobiotix has reported its latest shareholder information in compliance with French regulations. As of August 31, 2021, the company has 34,825,872 outstanding shares and 36,019,979 voting rights gross, with 36,010,846 voting rights net. Founded in 2003, Nanobiotix is a biotechnology firm focusing on innovative therapies, particularly for oncology, and is listed on both Euronext Paris and NASDAQ under the symbol NBTX.